SGLT-2 Inhibitors, An Issue of Heart Failure Clinics: The Clinics: Internal Medicine, cartea 18-4
Editat de Deepak L. Bhatt, Ragavendra R. Baligaen Limba Engleză Hardback – 10 oct 2022
Din seria The Clinics: Internal Medicine
- 70% Preț: 171.46 lei
- 70% Preț: 185.63 lei
- 18% Preț: 348.04 lei
- 18% Preț: 472.23 lei
- 18% Preț: 472.52 lei
- 18% Preț: 447.46 lei
- 5% Preț: 518.62 lei
- 5% Preț: 518.67 lei
- 5% Preț: 518.96 lei
- 5% Preț: 519.44 lei
- 5% Preț: 517.98 lei
- 5% Preț: 519.60 lei
- 5% Preț: 573.62 lei
- 5% Preț: 403.11 lei
- 5% Preț: 402.77 lei
- 18% Preț: 243.98 lei
- 5% Preț: 403.05 lei
- 18% Preț: 334.91 lei
- 5% Preț: 402.97 lei
- 5% Preț: 463.34 lei
- 5% Preț: 460.60 lei
- 5% Preț: 403.45 lei
- 5% Preț: 405.53 lei
- 5% Preț: 402.77 lei
- 5% Preț: 460.69 lei
- 18% Preț: 399.27 lei
- 5% Preț: 460.15 lei
- 5% Preț: 448.61 lei
- 5% Preț: 506.70 lei
- 5% Preț: 402.08 lei
- 5% Preț: 402.52 lei
- 5% Preț: 402.52 lei
- 5% Preț: 519.15 lei
- 5% Preț: 518.39 lei
- 5% Preț: 590.87 lei
- 5% Preț: 518.21 lei
- 5% Preț: 518.09 lei
- 21% Preț: 447.44 lei
- 22% Preț: 446.08 lei
- 5% Preț: 576.44 lei
- 5% Preț: 576.17 lei
- 5% Preț: 577.92 lei
- 5% Preț: 576.94 lei
- 5% Preț: 570.07 lei
- 5% Preț: 576.11 lei
- 5% Preț: 686.25 lei
- 18% Preț: 472.52 lei
- 5% Preț: 713.61 lei
- 5% Preț: 576.27 lei
- 5% Preț: 579.22 lei
Preț: 430.47 lei
Preț vechi: 453.13 lei
-5% Nou
Puncte Express: 646
Preț estimativ în valută:
82.38€ • 87.12$ • 68.72£
82.38€ • 87.12$ • 68.72£
Carte tipărită la comandă
Livrare economică 24 decembrie 24 - 07 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780323960465
ISBN-10: 0323960464
Pagini: 240
Dimensiuni: 178 x 254 mm
Greutate: 0.54 kg
Editura: Elsevier
Seria The Clinics: Internal Medicine
ISBN-10: 0323960464
Pagini: 240
Dimensiuni: 178 x 254 mm
Greutate: 0.54 kg
Editura: Elsevier
Seria The Clinics: Internal Medicine
Cuprins
Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors
Renoprotective Effects of SGLT2 Inhibitors
SGLT2 Inhibitors in Type 2 Diabetes Mellitus
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction
SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits
Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events
SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature
Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
SGLT2 Inhibitors and Safety in Older Patients
Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk
Renoprotective Effects of SGLT2 Inhibitors
SGLT2 Inhibitors in Type 2 Diabetes Mellitus
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction
SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits
Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events
SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature
Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
SGLT2 Inhibitors and Safety in Older Patients
Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk